HRP20210566T1 - Novi spojevi koji imaju trostruku aktivnost trombolize, antitromboze i uklanjanja radikala i njihova sinteza, nano- struktura i uporaba - Google Patents
Novi spojevi koji imaju trostruku aktivnost trombolize, antitromboze i uklanjanja radikala i njihova sinteza, nano- struktura i uporaba Download PDFInfo
- Publication number
- HRP20210566T1 HRP20210566T1 HRP20210566TT HRP20210566T HRP20210566T1 HR P20210566 T1 HRP20210566 T1 HR P20210566T1 HR P20210566T T HRP20210566T T HR P20210566TT HR P20210566 T HRP20210566 T HR P20210566T HR P20210566 T1 HRP20210566 T1 HR P20210566T1
- Authority
- HR
- Croatia
- Prior art keywords
- sequence
- ala
- pro
- compound
- lys
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 17
- 230000002537 thrombolytic effect Effects 0.000 title claims 8
- 239000003146 anticoagulant agent Substances 0.000 title claims 2
- 230000002292 Radical scavenging effect Effects 0.000 title 1
- 230000002785 anti-thrombosis Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000002086 nanomaterial Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 claims 6
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- 108010038807 Oligopeptides Proteins 0.000 claims 3
- 102000015636 Oligopeptides Human genes 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 108010091858 peptide Q Proteins 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- -1 L -Lys Chemical compound 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical group C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 1
- 229940127217 antithrombotic drug Drugs 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (14)
1. Spoj formule I:
[image]
naznačen time što T predstavlja vezujuću granu koja ima najmanje dvije grupe za vezanje;
Q predstavlja peptid koji trombolitičku aktivnost; i
R1 i R2 predstavljaju C1-4 alkil grupe, pri čemu su R1 i R2 iste ili različite;
pri čemu je najmanje jedna od grupa za vezanje amino grupa i preostale grupe za vezanje su karboksilne grupe ili amino grupe; i
pri čemu je peptid koji ima trombolitičku aktivnost odabran iz grupe koja se sastoji od oligopeptida koji sadrži PA (Pro-Ala) sekvencu, PAK (Pro-Ala-Lys) sekvencu, AKP (Ala-Lys-Pro) sekvencu ili KAP (Lys-Ala-Pro) sekvencu, i peptida koji ima ponovljene jedinice PAK sekvence, AKP sekvence ili KAP sekvence.
2. Spoj prema patentnom zahtjevu 1, naznačen time što je vezujuća grana L-Lys, L-Asp, ili L-Glu.
3. Spoj prema patentnom zahtjevu 1, naznačen time što je oligopeptid koji ima PA (Pro- Ala) sekvencu tripeptid koji ima sljedeću formulu Q1 ili Q2:
Pro-Ala-AA (Q1)
AA-Ala-Pro (Q2)
pri čemu je AA odabran iz grupe koja se sastoji od L-Ala, L-Val, L-Trp, L-Tyr, L-Pro, L-Phe, Gly, L-Ser, L-Ile, L-Thr, L-Lys, L-Leu, L-Gln, L-Asn , L-Asp, i L-Glu.
4. Spoj prema patentnom zahtjevu 1, naznačen time što su obje R1 i R2 metil grupe.
5. Spoj prema patentnom zahtjevu 4, naznačen time što je vezujuća grana L-Lys, L-Asp, ili L-Glu, i peptid koji ima trombolitičku aktivnost je tripeptid koji ima PA (Pro-Ala) sekvencu.
6. Spoj prema patentnom zahtjevu 5, naznačen time što spoj ima sljedeću formulu Ia, Ib, Ic, Id, Ie, If, Ig, ili Ih:
[image]
[image]
[image]
[image]
[image]
[image]
pri čemu je AA odabran iz grupe koja se sastoji od L-Ala, L-Val, L-Trp, L-Tyr, L-Pro, L-Phe, Gly, L-Ser, L-Ile, L-Thr, L-Lys, L-Leu, L-Gln, L-Asn , L-Asp, i L-Glu.
7. Spoj prema patentnom zahtjevu 6, naznačen time što spoj ima sljedeću formulu Ia:
[image]
pri čemu je AA L-Lys.
8. Farmaceutski pripravak, koji sadrži spoj prema bilo kojem od patentnih zahtjeva od 1 do 7, i farmaceutski prihvatljiv nosač.
9. Farmaceutski pripravak prema patentnom zahtjevu 8, naznačen time što je spoj u formi nanosferične strukture.
10. Farmaceutski pripravak prema patentnom zahtjevu 8 za uporabu kao trombolitički lijek, lijek za uklanjanje NO slobodnih radikala, ili antitrombotički lijek.
11. Farmaceutski pripravak prema patentnom zahtjevu 8 za uporabu kao lijek u liječenju moždanog udara ili cerebralnog infarkta.
12. Postupak za pripremu spoja koji ima formulu I prema patentnom zahtjevu 1, koji sadrži sljedeće korake:
(1) osiguravanje spoja koji ima sljedeću formulu II:
[image]
gdje R1 i R2 predstavljaju C1-4 alkil grupe, a R1 i R2 su iste ili različite;
(2) osiguravanje vezujuće grane T koja ima najmanje dvije grupe za vezanje, i peptida Q koji ima trombolitičku aktivnost, pri čemu vezujuća grana ima prvu grupu za vezanje i drugu grupu za vezanje;
(3) spajanje karboksilne grupe spoja koji ima formulu II sa prvom grupom za
vezanje vezujuće grane T da bi se formirao spoj koji ima sljedeću formulu IM-1:
[image]
pod odgovarajućim uvjetima prilikom odvijanja reakcije; i
(4) spajanje peptida Q koji ima trombolitičku aktivnost sa spojem koji ima formulu IM-1 pod odgovarajućim uvjetima prilikom odvijanja reakcije, pri čemu je jedan kraj peptida Q koji ima trombolitičku aktivnost spojen sa drugom grupom za vezanje vezujuće grane T da bi se formirao spoj koji ima formulu I.
13. Postupak za pripremu prema patentnom zahtjevu 12, naznačen time što je prva grupa za vezanje amino grupa, a druga grupa za vezanje je karboksilna ili amino grupa.
14. Postupak za pripremu prema patentnom zahtjevu 12, naznačen time što je peptid koji ima trombolitičku aktivnost odabran iz grupe koja se sastoji od oligopeptida koji ima PA (Pro- Ala) sekvencu, PAK (Pro-Ala-Lys) sekvencu, AKP (Ala-Lys-Pro) sekvencu ili KAP (Lys- Ala-Pro) sekvencu, i peptida koji ima ponovljene jedinice PAK sekvence, AKP sekvence ili KAP sekvence.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310225330 | 2013-06-05 | ||
| EP14807973.4A EP3006454B1 (en) | 2013-06-05 | 2014-06-03 | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof |
| PCT/CN2014/079098 WO2014194809A1 (zh) | 2013-06-05 | 2014-06-03 | 具有溶栓、抗栓和自由基清除三重活性的新型化合物、其合成、纳米结构和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210566T1 true HRP20210566T1 (hr) | 2021-06-25 |
Family
ID=52007559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210566TT HRP20210566T1 (hr) | 2013-06-05 | 2021-04-09 | Novi spojevi koji imaju trostruku aktivnost trombolize, antitromboze i uklanjanja radikala i njihova sinteza, nano- struktura i uporaba |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9890193B2 (hr) |
| EP (1) | EP3006454B1 (hr) |
| JP (1) | JP6510500B2 (hr) |
| KR (1) | KR102204781B1 (hr) |
| CN (1) | CN104231046B (hr) |
| AU (1) | AU2014277416B2 (hr) |
| BR (1) | BR112015027164B1 (hr) |
| CA (1) | CA2914004C (hr) |
| CY (1) | CY1123976T1 (hr) |
| DK (1) | DK3006454T3 (hr) |
| ES (1) | ES2847934T3 (hr) |
| HR (1) | HRP20210566T1 (hr) |
| HU (1) | HUE053351T2 (hr) |
| LT (1) | LT3006454T (hr) |
| MX (1) | MX362902B (hr) |
| PH (1) | PH12015502684B1 (hr) |
| PL (1) | PL3006454T3 (hr) |
| PT (1) | PT3006454T (hr) |
| RS (1) | RS61606B1 (hr) |
| RU (1) | RU2660901C2 (hr) |
| SI (1) | SI3006454T1 (hr) |
| TW (1) | TWI633889B (hr) |
| WO (1) | WO2014194809A1 (hr) |
| ZA (1) | ZA201507237B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608902A (zh) * | 2015-10-22 | 2017-05-03 | 彭莉 | 二羟基二甲基四氢异喹啉-3-甲酰-Lys(Lys),其合成,活性及应用 |
| CN106608905B (zh) * | 2015-10-22 | 2020-10-16 | 彭莉 | 四氢异喹啉-3-甲酰-k(grpak)rgdv,其合成,活性及应用 |
| JP6663774B2 (ja) | 2016-03-30 | 2020-03-13 | 東京エレクトロン株式会社 | 基板搬送方法及び基板処理システム |
| CN114555085A (zh) * | 2019-09-25 | 2022-05-27 | 顺天医药生技股份有限公司 | 包含溶栓肽-四氢异喹啉缀合物的药物组合物 |
| WO2021229013A1 (en) * | 2020-05-15 | 2021-11-18 | Synhelix | Peptidic scaffolds, processes for manufacturing the same, and uses thereof as soluble supports |
| JP2024510653A (ja) | 2021-03-22 | 2024-03-08 | ルモサ セラピューティクス カンパニー， リミテッド | 急性虚血性脳卒中を治療するｄｃ００９ |
| CN115403653A (zh) * | 2022-05-19 | 2022-11-29 | 首都医科大学 | D(+)-β-(3,4-二羟基苯基)-乳酰-Pro-Ala-Lys,其合成及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5222632B2 (hr) * | 1972-08-22 | 1977-06-18 | ||
| DE60205727T2 (de) | 2001-01-23 | 2006-06-29 | Eli Lilly And Co., Indianapolis | Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors |
| EP1469851B1 (en) | 2002-01-23 | 2006-10-11 | Eli Lilly And Company | Melanocortin receptor agonists |
| EP1578786A2 (en) * | 2002-12-23 | 2005-09-28 | Janssen Pharmaceutica N.V. | Heteroaryl peptidomimetics as thrombin receptor antagonists |
| CN101190895B (zh) | 2006-11-30 | 2010-05-26 | 首都医科大学 | N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 |
| CN101190941B (zh) * | 2006-11-30 | 2010-12-01 | 首都医科大学 | 具有溶血栓活性的多肽、其制备方法及应用 |
| CN101200493B (zh) | 2006-12-11 | 2011-11-09 | 首都医科大学 | （3s）-n-（l-氨基酰）-1，2，3，4-四氢异喹啉-3-羧酸、其制备方法及应用 |
| CN101497651B (zh) * | 2008-01-30 | 2012-06-27 | 首都医科大学 | 具有溶血栓活性的化合物、其制备方法、其应用 |
| CN102241740B (zh) * | 2008-01-30 | 2014-02-19 | 首都医科大学 | 具有溶血栓活性的化合物、其制备方法、其应用 |
| CN101899084B (zh) | 2009-05-26 | 2012-09-05 | 首都医科大学 | (3s)-1,2,3,4-四氢异喹啉-3-羧酸三肽缀合物及其制备方法和应用 |
| CN102120727B (zh) | 2010-01-07 | 2013-08-28 | 首都医科大学 | N-[(3s)-n-氨基酰-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用 |
| CN102127097A (zh) | 2010-01-15 | 2011-07-20 | 首都医科大学 | N-（3s-1,2,3,4-四氢异喹啉-3-甲酰基）氨基酸铜络合物及其制备方法和应用 |
| CN102477068B (zh) | 2010-11-30 | 2013-07-24 | 首都医科大学 | 用于制备溶血栓药物的氨基酸衍生物及其制备方法和应用 |
| DK2766346T3 (en) * | 2011-10-14 | 2017-07-03 | Bristol Myers Squibb Co | SUBSTITUTED TETRAHYDROISOQUINOL COMPOUNDS AS FACTOR XIA INHIBITORS |
| CN103145797B (zh) | 2011-12-07 | 2015-05-20 | 首都医科大学 | [(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]-Lys修饰的RGD四肽,其合成和在医学中的应用 |
| CN103450338B (zh) | 2012-05-29 | 2016-08-24 | 首都医科大学 | 杂环羧酸修饰的胸腺五肽，其制备，抗肿瘤作用和应用 |
| CN103450330B (zh) * | 2012-06-01 | 2016-05-25 | 首都医科大学 | 二羟基四氢异喹啉-3-甲酰氨基酸、其合成、抗血栓作用和应用 |
| CN103665107B (zh) * | 2012-09-05 | 2017-07-14 | 上海晟顺生物科技有限公司 | 同时具溶血栓、清除自由基和血栓靶向功能的新颖化合物及其制备方法和用途 |
| CN102887941A (zh) * | 2012-09-05 | 2013-01-23 | 永光制药有限公司 | Pak/咪唑啉/rgd三元缀合物及其制备方法和用途 |
-
2014
- 2014-06-03 LT LTEP14807973.4T patent/LT3006454T/lt unknown
- 2014-06-03 KR KR1020157035673A patent/KR102204781B1/ko active IP Right Grant
- 2014-06-03 AU AU2014277416A patent/AU2014277416B2/en active Active
- 2014-06-03 HU HUE14807973A patent/HUE053351T2/hu unknown
- 2014-06-03 JP JP2016517144A patent/JP6510500B2/ja active Active
- 2014-06-03 DK DK14807973.4T patent/DK3006454T3/da active
- 2014-06-03 PT PT148079734T patent/PT3006454T/pt unknown
- 2014-06-03 ES ES14807973T patent/ES2847934T3/es active Active
- 2014-06-03 CA CA2914004A patent/CA2914004C/en active Active
- 2014-06-03 MX MX2015015924A patent/MX362902B/es active IP Right Grant
- 2014-06-03 WO PCT/CN2014/079098 patent/WO2014194809A1/zh active Application Filing
- 2014-06-03 CN CN201410242169.8A patent/CN104231046B/zh active Active
- 2014-06-03 BR BR112015027164-2A patent/BR112015027164B1/pt active IP Right Grant
- 2014-06-03 PL PL14807973T patent/PL3006454T3/pl unknown
- 2014-06-03 RS RS20210349A patent/RS61606B1/sr unknown
- 2014-06-03 SI SI201431789T patent/SI3006454T1/sl unknown
- 2014-06-03 EP EP14807973.4A patent/EP3006454B1/en active Active
- 2014-06-03 RU RU2015147247A patent/RU2660901C2/ru active
- 2014-06-04 TW TW103119375A patent/TWI633889B/zh active
-
2015
- 2015-09-30 ZA ZA201507237A patent/ZA201507237B/en unknown
- 2015-12-01 PH PH12015502684A patent/PH12015502684B1/en unknown
- 2015-12-02 US US14/956,723 patent/US9890193B2/en active Active
-
2018
- 2018-01-03 US US15/861,300 patent/US10351594B2/en active Active
-
2019
- 2019-07-09 US US16/506,674 patent/US20200055895A1/en not_active Abandoned
-
2021
- 2021-03-22 CY CY20211100244T patent/CY1123976T1/el unknown
- 2021-04-08 US US17/225,775 patent/US20210355163A1/en not_active Abandoned
- 2021-04-09 HR HRP20210566TT patent/HRP20210566T1/hr unknown
-
2023
- 2023-03-09 US US18/181,494 patent/US20230312644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210566T1 (hr) | Novi spojevi koji imaju trostruku aktivnost trombolize, antitromboze i uklanjanja radikala i njihova sinteza, nano- struktura i uporaba | |
| Georgiadis et al. | Phosphinic peptides as potent inhibitors of zinc-metalloproteases | |
| AU2018200652B9 (en) | Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides | |
| Kwan et al. | Grassystatins A− C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation | |
| US6143721A (en) | Dolastatin 15 derivatives | |
| IN2014DN03424A (hr) | ||
| JPH08504415A (ja) | 新規のペプチド、該ペプチドの製造及び使用 | |
| RS53782B1 (en) | TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS | |
| GB0716897D0 (en) | Cancer imaging and treatment | |
| EA201300005A1 (ru) | Модулирующие иммуносупрессию соединения | |
| ATE254630T1 (de) | Cyclosporine | |
| JP2018510132A5 (hr) | ||
| Liu et al. | New pharmaceuticals approved by FDA in 2020: Small‐molecule drugs derived from amino acids and related compounds | |
| WO2010150233A3 (en) | Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof | |
| ES2691895T3 (es) | Peptidomiméticos en horquilla beta | |
| Viveros-Ceballos et al. | Stereoselective synthesis of α-amino-C-phosphinic acids and derivatives | |
| KR102214694B1 (ko) | 선택적인 엘라스타제 저해제로서 β-헤어핀 펩타이드 모방체 | |
| HUP0203060A2 (hu) | Késleltetett hatóanyag-leadású peptidkomplex, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény | |
| JPH07506580A (ja) | ドラスタチン誘導体 | |
| WO2013181404A3 (en) | COMPOSITIONS AND METHODS FOR PEPTIDE EXPRESSION AND PURIFICATION USING A TYPE lll SECRETION SYSTEM | |
| RU2012106605A (ru) | Аминокислотные и пептидные пролекарства галантамина и их применение | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| Matziari et al. | Shortcut to Fmoc-protected phosphinic pseudodipeptidic blocks | |
| MX2012001200A (es) | (aza)indolizinacarboxamidas ciclicas, su preparacion y su uso como agentes farmaceuticos. |